Trials that use: MMRM (mixed model for repeated measures)
New to this method? Read the tutorial →
23 results
- ASPECCTIndependent statistical analysis of ASPECCT, the randomized phase 3 comparison of panitumumab and cetuximab in patients with KRAS wild-type metastatic colorectal cancer, including non-inferiority analysis, hazard ratios, response, patient-reported outcomes, and safety.
- COMPASS-2Independent statistical analysis of COMPASS-2, evaluating bosentan added to sildenafil versus sildenafil monotherapy in pulmonary arterial hypertension, including time-to-event, functional, biomarker, quality-of-life, and safety results.
- DUO-EIndependent statistical analysis of the phase 3 DUO-E trial evaluating durvalumab with or without olaparib as maintenance therapy after first-line treatment of advanced and recurrent endometrial cancer.
- EMPEROR-PreservedA detailed statistical analysis of EMPEROR-Preserved, the randomized phase 3 trial of 10 mg empagliflozin versus placebo in patients with heart failure, including time-to-event outcomes, Cox models, recurrent-event analysis, MMRM, and interpretation.
- ENGAGEIndependent statistical analysis of the ENGAGE phase 3 trial of aducanumab in early Alzheimer's disease, including randomized trial design, CDR-SB and cognitive endpoints, MMRM methodology, confidence intervals, p-values, and safety.
- GOLDEN-3Independent statistical analysis of GOLDEN-3 (NCT02347761), a randomized phase 3 trial of nebulized SUN-101 in patients with COPD, including its FEV1 endpoint, MMRM methodology, multiplicity control, confidence intervals, and reported results.
- GOLDEN-4Independent statistical analysis of GOLDEN-4, a randomized phase 3 trial of nebulized SUN-101 in patients with COPD, including its MMRM methodology, primary FEV1 results, multiplicity approach, safety data, and statistical interpretation.
- INBUILDIndependent statistical analysis of the INBUILD phase 3 trial of nintedanib in patients with progressive fibrosing interstitial lung disease, including FVC decline, longitudinal modeling, time-to-event endpoints, logistic regression, safety, and interpretation.
- PARAGON-HFIndependent statistical analysis of PARAGON-HF, evaluating LCZ696 versus valsartan in heart failure with preserved ejection fraction, including primary and secondary endpoint analyses, statistical methods, interpretation, and limitations.
- PROMISE-2Independent statistical analysis of the PROMISE-2 phase 3 trial of ALD403 (eptinezumab) for the prevention of chronic migraine, including trial design, endpoints, ANCOVA, MMRM, Cochran-Mantel-Haenszel analyses, reported results, safety, and statistical interpretation.
- REACTComplete statistical analysis of the REACT trial (NCT01329029), evaluating roflumilast versus placebo in patients with chronic obstructive pulmonary disease treated with fixed LABA and inhaled glucocorticosteroid combinations.
- SALSAIndependent statistical analysis of the phase 3 SALSA trial of switching to dolutegravir/lamivudine fixed-dose combination from a current antiretroviral regimen in virologically suppressed adults with HIV-1 infection.
- SINGLEComplete statistical analysis of the SINGLE phase 3 trial comparing dolutegravir plus abacavir/lamivudine with Atripla in HIV-1 infection, including the Week 48 primary endpoint, later virologic suppression analyses, CD4 outcomes, non-inferiority methodology,…
- SOLOIST-WHFIndependent statistical analysis of SOLOIST-WHF (NCT03521934), evaluating sotagliflozin versus placebo in participants with type 2 diabetes and worsening heart failure. Includes trial design, registered endpoints, Cox, ANCOVA and MMRM methodology, reported results,…
- STEP 2Complete statistical analysis of STEP 2, the randomized phase 3 trial of semaglutide in people with type 2 diabetes and overweight or obesity, including trial design, primary endpoints, ANCOVA, MMRM, logistic regression,…
- STEP 3Complete statistical analysis of STEP 3 (NCT03611582), a phase 3 randomized trial evaluating semaglutide versus placebo for weight reduction in people with overweight or obesity, including endpoint definitions, ANCOVA, MMRM, logistic regression,…
- STEP 4Independent statistical analysis of STEP 4 (NCT03548987), a randomized phase 3 trial evaluating change in body weight with semaglutide 2.4 mg versus placebo in people with overweight or obesity.
- STEP 5Complete statistical analysis of the STEP 5 phase 3 trial of semaglutide versus placebo in adults with overweight or obesity, including trial design, primary endpoints, ANCOVA, MMRM, logistic regression, confidence intervals, and…
- SWITCH 1Independent statistical analysis of SWITCH 1 (NCT02034513), a randomized double-blind phase 3 crossover trial comparing insulin degludec with insulin glargine in type 1 diabetes, including its non-inferiority framework, Poisson regression, MMRM, McNemar…
- SWITCH 2Independent statistical analysis of SWITCH 2, a randomized double-blind crossover phase 3 trial comparing insulin degludec with insulin glargine in subjects with type 2 diabetes, including hypoglycaemia, HbA1c, crossover design, non-inferiority, and…
- TROPiCS-04Independent statistical analysis of TROPiCS-04, a randomized phase 3 trial of sacituzumab govitecan versus physician's choice of treatment in locally advanced or metastatic unresectable urothelial cancer.
- TULIPIndependent statistical analysis of the phase 3 TULIP trial of (vic-)trastuzumab duocarmazine versus physician's choice in participants with HER2-positive locally advanced or metastatic breast cancer, including progression-free survival, overall survival, response, quality…
- ZUMA-7Independent statistical analysis of ZUMA-7, the randomized phase 3 trial of axicabtagene ciloleucel versus standard of care therapy in relapsed/refractory diffuse large B-cell lymphoma, including event-free survival, response, overall survival, quality of…